Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 52-Week High – Still a Buy?

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $37.79 and last traded at $37.7670, with a volume of 1340480 shares. The stock had previously closed at $36.58.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: The FDA accepted Teva’s application for ecopipam and granted priority review for pediatric Tourette syndrome. The first-in-class therapy has a targeted decision date in late March 2027 and could address significant unmet need, strengthening Teva’s neuroscience pipeline. FDA accepts Teva’s NDA and grants priority review for ecopipam
• Positive Sentiment: The ecopipam priority designation could accelerate a potential launch and provide a new branded-growth driver if approved, particularly because it may become the first new pediatric Tourette syndrome treatment in more than a decade. Teva’s ecopipam wins FDA priority review
• Neutral Sentiment: Recent commentary notes that Teva’s gains this year have been supported by stronger branded-drug growth, an improving pipeline and better finances. However, generic-drug pressure and elevated debt remain important risks for investors. Teva rises year to date: buy, sell or hold
• Negative Sentiment: Teva settled patent litigation with Aurinia Pharmaceuticals concerning its proposed generic version of LUPKYNIS. Under the agreement, potential U.S. generic competition is delayed until December 2036, limiting Teva’s opportunity to generate near-term revenue from the product. Aurinia settles patent litigation with Teva

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of research reports. Weiss Ratings raised Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Finally, Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.22.

Teva Pharmaceutical Industries Price Performance

The company has a market capitalization of $42.86 billion, a PE ratio of 61.30, a PEG ratio of 4.01 and a beta of 0.86. The firm has a fifty day moving average of $33.76 and a two-hundred day moving average of $33.10. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.96 EPS for the current fiscal year.

Insider Activity

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.54% of the stock is owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $1,098,060,000. WCM Investment Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after purchasing an additional 26,813,522 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after buying an additional 7,255,083 shares during the period. Wellington Management Group LLP increased its position in shares of Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after buying an additional 6,878,304 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.